Hints and tips:
...Two US healthcare companies have brought new hope in the fight against coronavirus, with Johnson & Johnson announcing a potential vaccine that could be available early next year and Abbott Laboratories launching...
...Abbott Laboratories, Chevron and Gilead Sciences were also among those sharply increasing debt repayments....
...Laboratories last year....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...The deal comes at a time of major upheaval in the medical devices industry as large players such as Medtronic, Abbott Laboratories and Johnson & Johnson each try to narrow their focus to compete with smaller...
...A trio of deals worth a combined $45bn breathed fresh life into the healthcare mergers and acquisitions boom on Thursday as Abbott Laboratories, AbbVie and Sanofi all went shopping for assets....
...J&J has faced fierce competition from Medtronic, the world’s largest standalone medical device maker, as well as Abbott Laboratories and a large number of smaller operators....
...It has eschewed the trend to slim down into a more focused group, as Pfizer did when it sold its consumer products division to J&J for $17bn in 2006, and as Abbott Laboratories did when it spun its pharmaceuticals...
...In February, Mylan closed a $5.6bn deal to acquire certain non-US assets from Abbott Laboratories....
.... …………………………………………………………………………………………………………… Ben Hall, world news editor, picks: • Isis Inc: how oil fuels jihadi terrorists by Erika Solomon, Guy Chazan and Sam Jones• Why China’s ‘migrant miracle’ is...
...Laboratories of the US....
...Based just north of Chicago, Illinois, Hospira was spun out of Abbott Laboratories, the US healthcare group, in 2004 and has gone on to become the world’s largest producer of generic injectable medicines...
...Abbott Laboratories, which does $1bn a year in eye-related sales, is busy spinning off its branded pharma business, so it might be out of contention....
...And, given the valuations of nutritionals, it is little wonder that Abbott Laboratories should want to split itself into healthcare and pharmaceuticals companies....
...On Tuesday, Johnson & Johnson said that its medical device business was approaching a “trough”, as patients were choosing to move forward with knee and hip replacements that they had delayed....
...Johnson & Johnson has rejected calls to offer patent rights on its HIV medicines to generic drug companies through a “pool” designed to boost research and affordable access for patients....
...Most subsequent deals have been more targeted on particular products or regions, such as Sanofi’s purchase of Genzyme in 2011, which specialises in “orphan diseases”; Johnson & Johnson’s purchase of Synthes...
...Giants such as Johnson & Johnson, Abbott and Bristol-Myers Squibb, along with start-ups including Inhibitex, Achillion and Idenix, all have potential rivals to Incivek in the clinic....
...It will stimulate discussions on whether other diversified groups such as Novartis, Pfizer and Johnson & Johnson should pursue similar initiatives....
...Other producers, including Merck of Germany, Johnson & Johnson, and Abbott are also set to be targeted soon by rival versions of some of their most lucrative biological medicines....
...This justifies a premium not only to the likes of Merck, Pfizer and Eli Lilly, which face the most daunting gaps in future revenue, but also Abbott Laboratories and Bristol-Myers Squibb....
...Ms ’t Hoen told the Financial Times that Merck, Gilead and Tibotec, part of Johnson & Johnson, were among the companies that had expressed most support for the pool, which would ask them to assign their...
...The lack of competition now means new funds can often make a high double-digit return in a couple of months from even the most mainstream deals, such as the €4.5bn ($5.8bn) takeover by Abbott Laboratories...
...Abbott Laboratoriesfell 1.3 per cent to $51.12, Johnson & Johnson was 0.9 per cent lower at $64.78 and Eli Lilly lost 1.8 per cent to $35.38....
...Johnson....
International Edition